331 related articles for article (PubMed ID: 1689677)
21. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
Tarle M; Kraljić I
Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
[TBL] [Abstract][Full Text] [Related]
22. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
Tsuchiya N; Ohyama C; Habuchi T
Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer-associated markers.
Chu TM
Immunol Ser; 1990; 53():339-56. PubMed ID: 1713065
[TBL] [Abstract][Full Text] [Related]
24. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific antigen: a valuable clinical tool.
Oesterling JE
Oncology (Williston Park); 1991 Apr; 5(4):107-22; discussion 122, 125-6, 128. PubMed ID: 1714288
[TBL] [Abstract][Full Text] [Related]
26. [Tumor markers in prostate cancer].
Kuriyama M
Gan To Kagaku Ryoho; 1994 Sep; 21(12):1915-22. PubMed ID: 7521999
[TBL] [Abstract][Full Text] [Related]
27. Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer.
Kabalin JN
Geriatrics; 1992 Sep; 47(9):26-32. PubMed ID: 1380941
[TBL] [Abstract][Full Text] [Related]
28. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
29. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
30. [Role of prostate-specific antigen in prostatic carcinoma. Validity of an integrated methodologic approach and morpho-biological correlations].
Tomasino RM; Lo Bianco A; Cacciatore M; Pavone C; Carreca I; Morello V; Salvato M; Florena AM; Pavone-Macaluso M
Pathologica; 1989; 81(1072):109-26. PubMed ID: 2475847
[TBL] [Abstract][Full Text] [Related]
31. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
32. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
33. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
[TBL] [Abstract][Full Text] [Related]
34. Detecting prostate cancer by intracellular macrophage prostate-specific antigen (PSA): a more specific and sensitive marker than conventional serum total PSA.
Herwig R; Mitteregger D; Djavan B; Kramer G; Margreiter M; Leers MP; Glodny B; Haider DG; Hörl WH; Marberger M
Eur J Clin Invest; 2008 Jun; 38(6):430-7. PubMed ID: 18489403
[TBL] [Abstract][Full Text] [Related]
35. PSA excess in the differential diagnosis of prostate carcinoma.
Díaz F; Morell M; Rojo G
Arch Esp Urol; 1997 May; 50(4):415-8. PubMed ID: 9219422
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of serum prostate specific antigen as a tumour marker in prostatic carcinoma: a comparison with serum acid phosphatase.
Cooke RR; Nacey JN; Beeston RE; Delahunt B
N Z Med J; 1992 Sep; 105(941):345-7. PubMed ID: 1279493
[TBL] [Abstract][Full Text] [Related]
37. [Diagnostic value of prostatic specific antigen (PSA) in comparison to prostatic acid phosphatase (PAP) in prostatic cancer and adenoma].
Dutkiewicz S; Stepień K; Witeska A
Wiad Lek; 1992 Oct; 45(19-20):750-3. PubMed ID: 1284261
[TBL] [Abstract][Full Text] [Related]
38. [Prostate-specific antigen in prostatic pathology].
Teillac P; Peyret C; Leroy M; Najean Y; Le Duc A
Ann Urol (Paris); 1988; 22(3):193-6. PubMed ID: 2456712
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers for prostate cancer.
Leman ES; Getzenberg RH
J Cell Biochem; 2009 Sep; 108(1):3-9. PubMed ID: 19507229
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer.
Cohen RJ; Glezerson G; Haffejee Z
Arch Pathol Lab Med; 1992 Jan; 116(1):65-6. PubMed ID: 1370878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]